Issue Type: Balancing Innovation, Value, and Drug Prices
does this show up on site? or is this internal?
in challenge narrative
-
Biosimilars in Medicare Part D: pricing dynamics and considerations
-
Evaluating Industry’s Drug Pricing Claims
-
Production Plus Profit Pricing (P-quad) FAQ
-
Medicare Must Study Unproven, Expensive Alzheimer’s Drug
-
Value-Based Management of Specialty Drugs: Practical Considerations and Implications for Pharmacy
-
Trump’s Drug-Pricing Ideas Would Cost Taxpayers a Bundle
-
After 4 Years of Trump, Medicare and Medicaid Badly Need Attention
-
The Drugs at the Heart of Our Pricing Crisis
-
Biosimilars: Market Changes do not equal policy success
-
Curbing Biologic Drug Spending with P-quad